SEC filings and other documents

Q2 revenue dropped on delayed unit recognition, but a stronger second half is expected.

New CPT codes and recurring revenue initiatives drive growth despite lower year-over-year revenue.

Reimbursement clarity and international growth set the stage for profitability in 2026.

New CMS codes boost SRT reimbursement, setting stage for strong demand and future growth.

Revenue fell on paused domestic sales, but international growth and new reimbursement codes offer upside.

Q1 2025 marked by strategic investments, a 65% rise in FDA-driven treatments, and a path to profitability.

Record revenue and unit sales in 2024 set the stage for recurring growth via Fair Deal Agreements.

Q3 2024 revenue more than doubled year-over-year, with major new agreements fueling future growth.

SRT systems deliver high cure rates and strong financial growth in the expanding skin cancer market.

Revenue more than doubled in Q2 2024, with strong SRT sales and new recurring revenue model.